title: Antithrombotic and thrombolytic effects of a new proteolytic preparation Trombovazim (Russia).
abstract: We studied the antithrombotic and thrombolytic effects of Trombovazim, a highly-purified proteolytic enzyme preparation obtained by immobilization of bacterial proteinases (Bacillus) on polyethylene oxide with a molecular weight of 1.5 kDa. Blood absorption of the preparation was evaluated after intragastric administration. In vitro experiments showed that Trombovazim produces anticoagulant and thrombolytic effects, which manifested in inhibition of fibrin clot formation and acceleration of its lysis. Drug concentration in the blood was elevated from the 4th to the 7th hour after intragastric administration of Trombovazim in a dose of 2250 U/kg, being maximum by the 5th hour (0.044+/-0.011 U/ml). Course treatment with Trombovazim (1000 U intragastrically, twice daily for 3 days) had a thrombolytic effect on rats with experimental intravascular thrombosis. This effect was manifested in a decrease in thrombus weight and increase in the percent of rats with recanalization of the occluded carotid artery.
authors.affiliation: Institute of Pharmacology, Tomsk Research Center, Siberian Division of the Russian Academy of Medical Sciences, Tomsk, Russia. mbp2001@mail.ru
authors.forename: M B
authors.initials: MB
authors.lastname: Plotnikov
authors.forename: A M
authors.initials: AM
authors.lastname: Dygai
authors.forename: O I
authors.initials: OI
authors.lastname: Aliev
authors.forename: G A
authors.initials: GA
authors.lastname: Chernyshova
authors.forename: V I
authors.initials: VI
authors.lastname: Smol'yakova
authors.forename: A S
authors.initials: AS
authors.lastname: Vasil'ev
authors.forename: V A
authors.initials: VA
authors.lastname: Markov
authors.forename: E V
authors.initials: EV
authors.lastname: Vyshlov
authors.forename: E I
authors.initials: EI
authors.lastname: Vereschagin
authors.forename: D N
authors.initials: DN
authors.lastname: Kinsht
authors.forename: P G
authors.initials: PG
authors.lastname: Madonov
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D002339:Carotid Arteries / Q000187:drug effects / Q000503:physiopathology; D002341:Carotid Artery Thrombosis / Q000139:chemically induced / Q000188:drug therapy*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D005296:Ferrous Compounds; D005337:Fibrin / Q000378:metabolism; D008297:Male; D010447:Peptide Hydrolases / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D001426:Bacterial Proteins; D005296:Ferrous Compounds; D005337:Fibrin; D010447:Peptide Hydrolases; C029451:ferrous chloride